Please use this identifier to cite or link to this item:
Title: Prescription Rates of Cardiovascular Medications in a Large UK Primary Care Chronic Kidney Disease Cohort
Authors: Major, Rupert
Shepherd, David
Warwick, Graham
Brunskill, Nigel
First Published: 30-Apr-2016
Publisher: Karger Publishers
Citation: Nephron, 2016, 133 (1), pp. 15-22
Abstract: Background and Aims: Chronic kidney disease (CKD) is associated with increased cardiovascular (CV) risk. Guidelines have suggested the universal use of statins in CKD but aspirin's role is less well defined. The aim of this study was to determine prescription rates for statins and aspirin in a UK-based CKD cohort and to establish factors that influenced prescription rates. Methods: We used data from a UK primary care CKD cohort to study rates of prescription of statins and aspirin. Simple rates were initially calculated. Binary logistic regression was utilized with either statin or aspirin prescription as the outcome variable and covariates including demographic details and comorbidities. Results: There were 31,056 individuals in the cohort with at least one estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73 m², and 65.1% individuals had 2 eGFR results <60 ml/min/1.73 m² more than 3 months apart. Mean eGFR at baseline was 51.1 ml/min/1.73 m² (SD 9.1), and 64.9% had a diagnosis of hypertension (HTN), 18.8% had diabetes mellitus (DM) and 29.8% a history of CV disease. Statins were prescribed to 14,972 (48.2%) and aspirin to 11,023 (35.5%). The regression model suggested that CV disease, HTN and DM influenced the prescriptions of statins and aspirin but overall CKD stage, calculated by either eGFR or proteinuria, did not. Conclusions: Prescriptions of statins and aspirin in CKD is based more on the presence of comorbidities than the CKD severity. Further physician and patient education of the increased CV risk associated with CKD and its suitability for CV medication intervention is required.
DOI Link: 10.1159/000445387
ISSN: 1660-8151
eISSN: 2235-3186
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2016, Karger Publishers. Deposited with reference to the publisher’s archiving policy available on the SHERPA/RoMEO website.
Appears in Collections:Published Articles, Dept. of Health Sciences

Files in This Item:
File Description SizeFormat 
Baseline Drugs IRIS.pdfPost-review (final submitted author manuscript)634.73 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.